VSIG4+ tumor-associated macrophages mediate neutrophil infiltration and impair antigen-specific immunity in aggressive cancers through epigenetic regulation of SPP1
Abstract V-set and immunoglobulin domain-containing 4 (VSIG4) positive tumor-associated macrophage (VSIG4+ TAM) is an immunosuppressive subpopulation newly identified in aggressive cancers. However, the mechanism how VSIG4+ TAMs mediate immune evasion in aggressive cancers have not been fully elucid...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-02-01
|
| Series: | Journal of Experimental & Clinical Cancer Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13046-025-03303-z |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823861484102352896 |
|---|---|
| author | Zongfu Pan Jinming Chen Tong Xu Anqi Cai Bing Han Ying Li Ziwen Fang Dingyi Yu Shanshan Wang Junyu Zhou Yingying Gong Yulu Che Xiaozhou Zou Lei Cheng Zhuo Tan Minghua Ge Ping Huang |
| author_facet | Zongfu Pan Jinming Chen Tong Xu Anqi Cai Bing Han Ying Li Ziwen Fang Dingyi Yu Shanshan Wang Junyu Zhou Yingying Gong Yulu Che Xiaozhou Zou Lei Cheng Zhuo Tan Minghua Ge Ping Huang |
| author_sort | Zongfu Pan |
| collection | DOAJ |
| description | Abstract V-set and immunoglobulin domain-containing 4 (VSIG4) positive tumor-associated macrophage (VSIG4+ TAM) is an immunosuppressive subpopulation newly identified in aggressive cancers. However, the mechanism how VSIG4+ TAMs mediate immune evasion in aggressive cancers have not been fully elucidated. In our study, we found targeting VSIG4+ TAMs by VSIG4 deficiency or blockade remarkably limited tumor growth and metastasis, especially those derived from anaplastic thyroid cancer (ATC) and pancreatic cancer, two extremely aggressive types. Moreover, the combination of VSIG4 blockade with a BRAF inhibitor synergistically enhanced anti-tumor activity in ATC-tumor bearing mice. VSIG4 deficiency recovered the antigen presentation (B2m, H2-k1, H2-d1) of TAMs and activated antigen-specific CD8+ T cells by promoting their in vivo proliferation and intratumoral infiltration. Notably, loss of VSIG4 in TAMs significantly reduced the production of lactate and histone H3 lysine 18 lactylation, resulting the decreased transcription of SPP1 mediated by STAT3, which collectively disrupted the cell-cell interactions between TAMs and neutrophils. Further combination of VSIG4 with SPP1 blockade synergistically boosted anti-tumor activity. Overall, our studies demonstrate the epigenetic regulation function of VSIG4 confers on TAMs an alternative pattern, beyond the checkpoint role of VSIG4, to shape the immunosuppressive tumor microenvironment and impair antigen-specific immunity against aggressive cancers. Graphical abstract |
| format | Article |
| id | doaj-art-927869a542d54dd4804fe1b9a6c0d921 |
| institution | Kabale University |
| issn | 1756-9966 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Experimental & Clinical Cancer Research |
| spelling | doaj-art-927869a542d54dd4804fe1b9a6c0d9212025-02-09T12:59:54ZengBMCJournal of Experimental & Clinical Cancer Research1756-99662025-02-0144111910.1186/s13046-025-03303-zVSIG4+ tumor-associated macrophages mediate neutrophil infiltration and impair antigen-specific immunity in aggressive cancers through epigenetic regulation of SPP1Zongfu Pan0Jinming Chen1Tong Xu2Anqi Cai3Bing Han4Ying Li5Ziwen Fang6Dingyi Yu7Shanshan Wang8Junyu Zhou9Yingying Gong10Yulu Che11Xiaozhou Zou12Lei Cheng13Zhuo Tan14Minghua Ge15Ping Huang16Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital), Hangzhou Medical CollegeCenter for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital), Hangzhou Medical CollegeCenter for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital), Hangzhou Medical CollegeCenter for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital), Hangzhou Medical CollegeCenter for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital), Hangzhou Medical CollegeCenter for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital), Hangzhou Medical CollegeCenter for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital), Hangzhou Medical CollegeCenter for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital), Hangzhou Medical CollegeCenter for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital), Hangzhou Medical CollegeCenter for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital), Hangzhou Medical CollegeCenter for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital), Hangzhou Medical CollegeCenter for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital), Hangzhou Medical CollegeCenter for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital), Hangzhou Medical CollegeCenter for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital), Hangzhou Medical CollegeOtolaryngology & Head and Neck Center, Cancer Center, Department of Head and Neck Surgery, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital), Hangzhou Medical CollegeOtolaryngology & Head and Neck Center, Cancer Center, Department of Head and Neck Surgery, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital), Hangzhou Medical CollegeCenter for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital), Hangzhou Medical CollegeAbstract V-set and immunoglobulin domain-containing 4 (VSIG4) positive tumor-associated macrophage (VSIG4+ TAM) is an immunosuppressive subpopulation newly identified in aggressive cancers. However, the mechanism how VSIG4+ TAMs mediate immune evasion in aggressive cancers have not been fully elucidated. In our study, we found targeting VSIG4+ TAMs by VSIG4 deficiency or blockade remarkably limited tumor growth and metastasis, especially those derived from anaplastic thyroid cancer (ATC) and pancreatic cancer, two extremely aggressive types. Moreover, the combination of VSIG4 blockade with a BRAF inhibitor synergistically enhanced anti-tumor activity in ATC-tumor bearing mice. VSIG4 deficiency recovered the antigen presentation (B2m, H2-k1, H2-d1) of TAMs and activated antigen-specific CD8+ T cells by promoting their in vivo proliferation and intratumoral infiltration. Notably, loss of VSIG4 in TAMs significantly reduced the production of lactate and histone H3 lysine 18 lactylation, resulting the decreased transcription of SPP1 mediated by STAT3, which collectively disrupted the cell-cell interactions between TAMs and neutrophils. Further combination of VSIG4 with SPP1 blockade synergistically boosted anti-tumor activity. Overall, our studies demonstrate the epigenetic regulation function of VSIG4 confers on TAMs an alternative pattern, beyond the checkpoint role of VSIG4, to shape the immunosuppressive tumor microenvironment and impair antigen-specific immunity against aggressive cancers. Graphical abstracthttps://doi.org/10.1186/s13046-025-03303-zImmunotherapyMacrophageImmune checkpointVSIG4Reprogramming |
| spellingShingle | Zongfu Pan Jinming Chen Tong Xu Anqi Cai Bing Han Ying Li Ziwen Fang Dingyi Yu Shanshan Wang Junyu Zhou Yingying Gong Yulu Che Xiaozhou Zou Lei Cheng Zhuo Tan Minghua Ge Ping Huang VSIG4+ tumor-associated macrophages mediate neutrophil infiltration and impair antigen-specific immunity in aggressive cancers through epigenetic regulation of SPP1 Journal of Experimental & Clinical Cancer Research Immunotherapy Macrophage Immune checkpoint VSIG4 Reprogramming |
| title | VSIG4+ tumor-associated macrophages mediate neutrophil infiltration and impair antigen-specific immunity in aggressive cancers through epigenetic regulation of SPP1 |
| title_full | VSIG4+ tumor-associated macrophages mediate neutrophil infiltration and impair antigen-specific immunity in aggressive cancers through epigenetic regulation of SPP1 |
| title_fullStr | VSIG4+ tumor-associated macrophages mediate neutrophil infiltration and impair antigen-specific immunity in aggressive cancers through epigenetic regulation of SPP1 |
| title_full_unstemmed | VSIG4+ tumor-associated macrophages mediate neutrophil infiltration and impair antigen-specific immunity in aggressive cancers through epigenetic regulation of SPP1 |
| title_short | VSIG4+ tumor-associated macrophages mediate neutrophil infiltration and impair antigen-specific immunity in aggressive cancers through epigenetic regulation of SPP1 |
| title_sort | vsig4 tumor associated macrophages mediate neutrophil infiltration and impair antigen specific immunity in aggressive cancers through epigenetic regulation of spp1 |
| topic | Immunotherapy Macrophage Immune checkpoint VSIG4 Reprogramming |
| url | https://doi.org/10.1186/s13046-025-03303-z |
| work_keys_str_mv | AT zongfupan vsig4tumorassociatedmacrophagesmediateneutrophilinfiltrationandimpairantigenspecificimmunityinaggressivecancersthroughepigeneticregulationofspp1 AT jinmingchen vsig4tumorassociatedmacrophagesmediateneutrophilinfiltrationandimpairantigenspecificimmunityinaggressivecancersthroughepigeneticregulationofspp1 AT tongxu vsig4tumorassociatedmacrophagesmediateneutrophilinfiltrationandimpairantigenspecificimmunityinaggressivecancersthroughepigeneticregulationofspp1 AT anqicai vsig4tumorassociatedmacrophagesmediateneutrophilinfiltrationandimpairantigenspecificimmunityinaggressivecancersthroughepigeneticregulationofspp1 AT binghan vsig4tumorassociatedmacrophagesmediateneutrophilinfiltrationandimpairantigenspecificimmunityinaggressivecancersthroughepigeneticregulationofspp1 AT yingli vsig4tumorassociatedmacrophagesmediateneutrophilinfiltrationandimpairantigenspecificimmunityinaggressivecancersthroughepigeneticregulationofspp1 AT ziwenfang vsig4tumorassociatedmacrophagesmediateneutrophilinfiltrationandimpairantigenspecificimmunityinaggressivecancersthroughepigeneticregulationofspp1 AT dingyiyu vsig4tumorassociatedmacrophagesmediateneutrophilinfiltrationandimpairantigenspecificimmunityinaggressivecancersthroughepigeneticregulationofspp1 AT shanshanwang vsig4tumorassociatedmacrophagesmediateneutrophilinfiltrationandimpairantigenspecificimmunityinaggressivecancersthroughepigeneticregulationofspp1 AT junyuzhou vsig4tumorassociatedmacrophagesmediateneutrophilinfiltrationandimpairantigenspecificimmunityinaggressivecancersthroughepigeneticregulationofspp1 AT yingyinggong vsig4tumorassociatedmacrophagesmediateneutrophilinfiltrationandimpairantigenspecificimmunityinaggressivecancersthroughepigeneticregulationofspp1 AT yuluche vsig4tumorassociatedmacrophagesmediateneutrophilinfiltrationandimpairantigenspecificimmunityinaggressivecancersthroughepigeneticregulationofspp1 AT xiaozhouzou vsig4tumorassociatedmacrophagesmediateneutrophilinfiltrationandimpairantigenspecificimmunityinaggressivecancersthroughepigeneticregulationofspp1 AT leicheng vsig4tumorassociatedmacrophagesmediateneutrophilinfiltrationandimpairantigenspecificimmunityinaggressivecancersthroughepigeneticregulationofspp1 AT zhuotan vsig4tumorassociatedmacrophagesmediateneutrophilinfiltrationandimpairantigenspecificimmunityinaggressivecancersthroughepigeneticregulationofspp1 AT minghuage vsig4tumorassociatedmacrophagesmediateneutrophilinfiltrationandimpairantigenspecificimmunityinaggressivecancersthroughepigeneticregulationofspp1 AT pinghuang vsig4tumorassociatedmacrophagesmediateneutrophilinfiltrationandimpairantigenspecificimmunityinaggressivecancersthroughepigeneticregulationofspp1 |